Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023GlobeNewsWire • 02/14/23
Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal MetastasesGlobeNewsWire • 02/01/23
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent GlioblastomaGlobeNewsWire • 01/18/23
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyGlobeNewsWire • 11/19/22
Plus Therapeutics to Provide Update on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyGlobeNewsWire • 11/02/22
Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNLGlobeNewsWire • 10/26/22
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 10/20/22
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine CongressGlobeNewsWire • 10/19/22
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022GlobeNewsWire • 10/06/22
Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness MonthGlobeNewsWire • 10/05/22
Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear MedicineGlobeNewsWire • 10/04/22
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of TexasGlobeNewsWire • 09/22/22
Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022GlobeNewsWire • 09/12/22
Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22
Plus Therapeutics Announces Summary of FDA Meeting on Company's cGMP Manufacturing Process for Lead Drug CandidateGlobeNewsWire • 08/29/22
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022GlobeNewsWire • 08/23/22
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain MetastasesGlobeNewsWire • 08/13/22